Injectable & Oral Kinetics

Drostanolone—chemically designated as 2-alpha-methyl-4,5-alpha-dihydrotestosterone—occupies a unique clinical and athletic niche among parenteral anabolic-androgenic steroids. Originally developed and approved under the trade name Masteron for the palliative treatment of estrogen-receptor-positive mammary carcinoma in postmenopausal women, Drostanolone has evolved into a cornerstone compound of modern bodybuilding contest preparation and strength-to-weight-class athletics. Its physiological value extends far beyond […]

Among the entire pharmacopoeia of synthetic anabolic-androgenic steroids developed during the golden era of twentieth-century steroid chemistry, Methenolone (widely recognized under its Schering trade names Primobolan Depot for the injectable enanthate ester and Primobolan S for the oral acetate ester) stands apart for its exceptional therapeutic index. Engineered specifically to dissociate myotrophic tissue building from […]

When native steroid hormones such as testosterone or dihydrotestosterone are ingested orally, more than 95 % of the dose is inactivated before reaching the systemic arterial circulation. Absorbed through the intestinal enterocytes into the mesenteric venous drainage, the steroid molecules travel directly via the hepatic portal vein into the liver sinusoids, where hepatic 17-beta-hydroxysteroid dehydrogenase […]

The pharmacokinetic behaviour of parenteral anabolic-androgenic steroids (AAS) is frequently oversimplified to a single half-life figure quoted in textbooks. In clinical reality, the serum concentration-time profile of an intramuscular steroid injection follows a flip-flop pharmacokinetic model: because the enzymatic cleavage of the ester bond by plasma esterases occurs almost instantaneously once the molecule enters the […]